|
Market Closed -
Nasdaq
16:00:00 2026-10-20 EDT
|
5-day change | 1st Jan Change | ||
| 14.62 USD | +7.34% |
|
-1.08% | +293.01% |
| 10-16 | Erasca Chief Operating Officer to Depart; Shares Fall | MT |
| 10-16 | Erasca, Inc. Announces Termination of Nicholas Chetwyn as Chief Operating Officer, Effective November 2, 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 5.11B | - | - | - | - | - |
| 66.34B | |||||
| 52.92B | |||||
| 54.82B | |||||
| 44.09B | |||||
| 43.72B |
- Stock Market
- Stocks
- ERAS Stock
- Charts Erasca, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
